Properties (57)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:chemicalFormula |
C22H24ClN5O2S
|
| gptkbp:clinicalTrials |
pediatric patients
adult patients Phase 1/2 NCT02121100 NCT02122913 NCT02236873 NCT02278024 NCT02278037 NCT02278050 NCT02278063 NCT02568267 NCT02576431 NCT02637687 |
| gptkbp:contraindication |
anemia
headache muscle pain weight loss rash joint pain insomnia dry mouth weight gain thrombocytopenia neutropenia severe liver impairment hypersensitivity reactions concurrent use of strong CYP3A4 inhibitors concurrent use of strong CYP3A4 inducers hypersensitivity_to_larotrectinib |
| gptkbp:developedBy |
gptkb:Bayer
|
| gptkbp:drugInterdiction |
metabolized by CYP3A4
high oral bioavailability selective TRK inhibition |
| gptkbp:formulation |
tablet
capsule |
| https://www.w3.org/2000/01/rdf-schema#label |
larotrectinib
|
| gptkbp:isATypeOf |
1257038-29-5
|
| gptkbp:lastProduced |
2018
|
| gptkbp:mandates |
solid tumors
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:route |
oral
|
| gptkbp:sells |
Vitrakvi
|
| gptkbp:sideEffect |
dizziness
fatigue nausea vomiting constipation increased liver enzymes |
| gptkbp:targets |
gptkb:NTRK_gene_fusions
|
| gptkbp:triggerType |
inhibitor of tropomyosin receptor kinases (TRK)
|
| gptkbp:usedFor |
treatment of TRK fusion-positive cancers
|